Consumers' risk perceptions of prescription and over-the-counter medications

Journal of Pharmacy Technology

Volumn 23, Issue 3, 2007, Pages 142-147

  Droege, Marcus ^a   Maniscalco, Maria ^a   Daniel, Karen L ^a   Baldwin, H John ^a  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; DIPHENHYDRAMINE; FAMOTIDINE; LORATADINE; NICOTINE GUM; NON PRESCRIPTION DRUG; PARACETAMOL; PAROXETINE; RECOMBINANT ERYTHROPOIETIN; SERTRALINE; SIMVASTATIN;

ARTICLE; CONSUMER; CORRELATION ANALYSIS; DECISION MAKING; DRUG INFORMATION; DRUG MARKETING; DRUG USE; HEALTH HAZARD; HEALTH SURVEY; HUMAN; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PERCEPTION; PRESCRIPTION; RISK; RISK BENEFIT ANALYSIS; UNITED STATES;

EID: 34347373761     PISSN: 87551225     EISSN: None     Source Type: Journal    
DOI: 10.1177/875512250702300303     Document Type: Article

References (27)

1. Slovic P, Fischhoff B, Lichtenstein S. Facts and fears: understanding perceived risk. Paper presented at: Societal Risk Assessment, 1979. Warren, MI: General Motors Research Laboratories, 1979.
2. Conchar MP, Zinkhan GM, Peters C, Olavarrieta S. An integrated framework for the conceptualization of consumers' perceived-risk processing. J Acad Market Sci 2004;32:418-36.
3. Charupatanapong N, Rascati K. An analysis of consumers' risk perceptions of their self-medication practices. J Pharm Market Manage 1991;5:53-78.
4. Cunningham S. The major dimension of perceived risk. In: Cox D, ed. Risk taking and information handling in consumer behavior. Boston: Harvard University Graduate School of Business Administration, 1967:82-108.
5. Bettman J. Perceived risk and its components: model and empirical test. J Market Res 1973;10:184-90.
6. Cox D. Risk taking and information handling in consumer behavior. Boston: Harvard University Press, 1967.
7. Slovic P. The legitimacy of public perceptions of risk. J Pesticide Ref 1990;10:13-5.
8. Ganther JM, Kreling DH. Consumer perceptions of risk and required cost savings for generic prescription drugs. J Am Pharm Assoc 2000;40:378-83.
9. Knapp DE, Baird JT Jr, Winter WJ. Consumers' methods of self-medication. Drug Inf J 1976;10:27-32.
10. Grahn J. Relationship of consumers' perceptions of drugs to drug use. Public Health Rep 1983;98:85-90.
11. United States Code, Title 42 §§1396r-8(g)(2).
12. Baldwin HJ, Droege M, Daniel KL. A message from the Vioxx case (letter). Am J Health Syst Pharm 2006;63:503. DOI 10.2146/ajhp050427
13. The Dichter Institute of Motivational Research, Inc. Communicating the value of comprehensive pharmaceutical services to the consumer. Washington, DC: American Pharmaceutical Association, 1973.
14. Humphreys A, Boersig C. 10th Annual report on DTC. Med Ad News 2004;23:40-53.
15. Rosenthal M, Berndt E, Donohue J, Frank R, Epstein A. Promotion of prescription drugs to consumers. N Engl J Med 2002;346: 498-505. DOI 10.1056/NEJMsa012075
16. Palumbo F, Mullins C. The development of direct-to-consumer prescription drug advertising regulation. Food Drug Law J 2002; 57:423-44.
17. Brody D. The patient's role in clinical decision-making. Ann Intern Med 1980;93:718-22.
18. Hollon M. Direct-to-consumer marketing of prescription drugs: creating consumer demand. JAMA 1999;281:382-4. DOI 10.1001/jama.281.4.382
19. Desselle SP. The interaction of direct-to-consumer prescription drug advertising and stakeholders in the medication use process. Res Soc Adm Pharm 2005;1:135-8. DOI 10.1016/j.sapharm.2005.03.001
20. Young HN, Lipowski EE, Cline RJW. Using social cognitive theory to explain consumers' behavioral intentions in response to direct-to-consumer prescription drug advertising. Res Soc Adm Pharm 2005;1:270-88. DOI 10.1016/j.sapharm.2005.03.011
21. Hansen R, Droege M. Methodological challenges surrounding direct-to-consumer advertising - the measurement conundrum. Res Soc Adm Pharm 2005;1:331-47. DOI 10.1016/j.sapharm.2005.03.005
22. Mitchell V. Consumer perceived risk: conceptualisations and models. Eur J Market 1999;33:163-95. DOI 10.1108/03090569910249229
23. Morris L. Survey of patients' receipt of prescription drug information. Med Care 1982;20:596-605.
24. Yavas U, Riecken G, Babakus E. Efficacy of perceived risk as a correlate of reported donation behavior: an empirical analysis. J Acad Market Sci 1993;21:65-70.
25. Davis J. Riskier than we think? The relationship between risk statement completeness and perceptions of direct to consumer advertised prescription drugs. J Health Commun 2000;5:349-69. DOI 10.1080/10810730050199141
26. Cosler LE, Schulz RM, Baldwin HJ, Cohen SH. Consumer preference for personal drug information source: relationship to perceived importance of drug class. Drug Intell Clin Pharm 1986;20: 138-42.
27. Baldwin HJ, Cosier LE, Schulz RM. Opinion leadership in medication information. Comm Q 1987;35:84-102.